iCover as Bridging Stent Graft in Fenestrated Endovascular Aortic Aneurysm Repair.

FEVAR bridging stent graft endoleak fenestrated endovascular aneurysm repair iCover stent graft in-hospital mortality technical success

Journal

Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists
ISSN: 1545-1550
Titre abrégé: J Endovasc Ther
Pays: United States
ID NLM: 100896915

Informations de publication

Date de publication:
06 Sep 2024
Historique:
medline: 6 9 2024
pubmed: 6 9 2024
entrez: 6 9 2024
Statut: aheadofprint

Résumé

Complex endovascular repair with fenestrated or branched stent grafts is a common approach for treating various types of aortic aneurysms. Bridging stent grafts (BSs) are crucial in connecting aortic endoprosthesis to target vessels, yet current options have demonstrated significant complications. This retrospective single-center study evaluates the initial outcomes and durability of the iCover stent graft (iCover-SG) when used as a BS in fenestrated endovascular aneurysm repair (FEVAR). Retrospective analysis screened procedures for complex aortic aneurysms between August 2021 and January 2024. Patients who underwent FEVAR with iCover-SG as BS were included. Primary and secondary endpoints focused on freedom from iCover-SG-related target vessel instability, technical success, and postoperative outcomes. Within the cohort of 28 patients, 94 iCover-SGs were used as BS, supplying 87 target vessels. The freedom from iCover-SG-related target vessel instability throughout the study reached 94% (82/87). Technical success rates were notably high, with primary success achieved in 94% of cases and secondary success in 99%. Over the follow-up duration, there were instances necessitating reintervention related to iCover-SG, including 4 cases of endoleak, 2 cases of T1cEL, and 2 cases of T3cEL. In-hospital mortality was 7% (n=4), with 2 cases attributed to intraoperative complications. Importantly, no deaths were directly attributed to iCover-SG-related issues. The iCover-SG demonstrates promising initial outcomes as a BS in FEVAR, with high technical success rates and satisfactory rates of target vessel instability. Continued monitoring and further studies are warranted to assess long-term durability and outcomes. This study shows that the iCover stent graft achieves satisfactory technical success and target vessel stability in the short- and mid-term when used as a bridging stent graft in FEVAR procedures. Its successful integration into clinical practice broadens the range of available options, providing clinicians with more versatile tools for managing complex endovascular aortic aneurysms. This expanded selection of bridging stent grafts allows for more personalised treatment strategies, improving procedural precision and patient outcomes. The iCover stent graft's reliable performance highlights its potential as a valuable addition to current endovascular techniques, ultimately enhancing patient care in challenging cases.

Sections du résumé

BACKGROUND UNASSIGNED
Complex endovascular repair with fenestrated or branched stent grafts is a common approach for treating various types of aortic aneurysms. Bridging stent grafts (BSs) are crucial in connecting aortic endoprosthesis to target vessels, yet current options have demonstrated significant complications.
OBJECTIVE UNASSIGNED
This retrospective single-center study evaluates the initial outcomes and durability of the iCover stent graft (iCover-SG) when used as a BS in fenestrated endovascular aneurysm repair (FEVAR).
METHODS UNASSIGNED
Retrospective analysis screened procedures for complex aortic aneurysms between August 2021 and January 2024. Patients who underwent FEVAR with iCover-SG as BS were included. Primary and secondary endpoints focused on freedom from iCover-SG-related target vessel instability, technical success, and postoperative outcomes.
RESULTS UNASSIGNED
Within the cohort of 28 patients, 94 iCover-SGs were used as BS, supplying 87 target vessels. The freedom from iCover-SG-related target vessel instability throughout the study reached 94% (82/87). Technical success rates were notably high, with primary success achieved in 94% of cases and secondary success in 99%. Over the follow-up duration, there were instances necessitating reintervention related to iCover-SG, including 4 cases of endoleak, 2 cases of T1cEL, and 2 cases of T3cEL. In-hospital mortality was 7% (n=4), with 2 cases attributed to intraoperative complications. Importantly, no deaths were directly attributed to iCover-SG-related issues.
CONCLUSION UNASSIGNED
The iCover-SG demonstrates promising initial outcomes as a BS in FEVAR, with high technical success rates and satisfactory rates of target vessel instability. Continued monitoring and further studies are warranted to assess long-term durability and outcomes.
CLINICAL IMPACT CONCLUSIONS
This study shows that the iCover stent graft achieves satisfactory technical success and target vessel stability in the short- and mid-term when used as a bridging stent graft in FEVAR procedures. Its successful integration into clinical practice broadens the range of available options, providing clinicians with more versatile tools for managing complex endovascular aortic aneurysms. This expanded selection of bridging stent grafts allows for more personalised treatment strategies, improving procedural precision and patient outcomes. The iCover stent graft's reliable performance highlights its potential as a valuable addition to current endovascular techniques, ultimately enhancing patient care in challenging cases.

Identifiants

pubmed: 39239963
doi: 10.1177/15266028241270862
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

15266028241270862

Déclaration de conflit d'intérêts

Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: B.R. is proctor for Terumo Aortic and Cook Medical. A.Z. is a proctor for Artivion, Terumo Aortic, Cook Medical, Lombard/Endovastec/Microport, and iVascular. He is a member of an Advisory Board for Medtronic, Artivion, and iVascular.

Auteurs

Anna-Leonie Menges (AL)

Department of Vascular Surgery, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

Vincent Landré (V)

Department of Vascular Surgery, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

Lorenz Meuli (L)

Department of Vascular Surgery, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

Alexander Zimmermann (A)

Department of Vascular Surgery, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

Benedikt Reutersberg (B)

Department of Vascular Surgery, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

Classifications MeSH